Modafinil Biogaran (Modafinil)

• Modafinil acts on central nervous system pathways that regulate wakefulness, making it useful for several sleep‑related disorders.
• Narcolepsy: reduces excessive daytime sleepiness and improves alertness.
• Obstructive sleep apnea: mitigates residual sleepiness when used with standard therapy.
• Shift work sleep disorder: helps maintain alertness during atypical work hours.

• Modafinil promotes wakefulness primarily by inhibiting the reuptake of dopamine, thereby increasing extracellular dopamine levels. It also modulates orexin, histamine, and norepinephrine pathways, enhancing neuronal activity in brain regions that control arousal and alertness without directly stimulating adrenergic receptors.

Modafinil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal upset.
• Insomnia: difficulty initiating or maintaining sleep.
• Anxiety: feelings of nervousness or tension.
• Dizziness: transient light‑headedness.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Rash or severe skin reactions, including Stevens‑Johnson syndrome.
• Psychiatric symptoms such as hallucinations or mania.
• Cardiovascular events like hypertension or arrhythmia.
• Severe allergic reaction (anaphylaxis).
• Liver injury with elevated transaminases.
• Persistent mood changes or depression.

• Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients for adverse events.
• Assess cardiovascular status: screen for hypertension or arrhythmias.
• Monitor psychiatric history: avoid in patients with uncontrolled psychosis.
• Avoid abrupt discontinuation: taper to reduce rebound sleepiness.
• Use caution in hepatic impairment: dose adjustment may be required.
• Pregnancy and lactation: only if benefit outweighs risk.
• Store at room temperature: keep in the original pack, protect from moisture.

Modafinil can alter the metabolism of several concomitant medicines, requiring careful review of a patient’s medication list.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase modafinil levels.
• CYP2C19 inhibitors (e.g., fluvoxamine): can raise plasma concentrations.
• Hormonal contraceptives: reduced efficacy, consider alternative birth control.
• Monoamine oxidase inhibitors: risk of serotonin syndrome.
• Antacids containing aluminum or magnesium: may affect absorption.

Moderate Interactions (Monitor Closely)

• CYP2D6 substrates (e.g., codeine): possible altered metabolism.
• Antihypertensives: may reduce blood pressure control.
• Antidepressants (SSRIs, SNRIs): monitor for increased side effects.
• Antiepileptic drugs: potential changes in seizure threshold.
• Alcohol: may exacerbate central nervous system effects.